• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Personalized medicine for advanced prostate cancer

Research Project

Project/Area Number 15K10576
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionThe University of Tokyo

Principal Investigator

Fujimura Tetsuya  東京大学, 医学部附属病院, 准教授 (50376448)

Co-Investigator(Kenkyū-buntansha) 浦野 友彦  国際医療福祉大学, 医学部, 主任教授 (20334386)
高山 賢一  地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (50508075)
Co-Investigator(Renkei-kenkyūsha) Inoue Satoshi  東京大学, 医学部附属病院, 特任教授 (40251251)
Yamada Yuta  東京大学, 医学部附属病院, 助教 (10376452)
Kumagai Jimpei  東京大学, 医学部附属病院, 助教 (10323552)
Takahashi Satoru  日本大学, 医学部附属病院, 教授 (50197141)
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords前立腺癌 / アンドロゲン / エストロゲン / ドセタキセル / エピゲノム / 分子診断 / 個別化治療
Outline of Final Research Achievements

Although long non-coding RNAs (lncRNAs) have been associated with a variety of cancers, the interplay between lncRNAs and androgen receptor signaling in prostate cancer is still unclear. We identified an androgen-dependent lncRNA, POTEF-AS1, whose expression was regulated by androgen receptor in two androgen-dependent cells by using directional RNA sequencing analysis. POTEF-AS1 promoted cell growth, repressed genes related to the Toll-like receptor signaling and apoptosis pathways, and inhibited apoptosis in docetaxel-treated LNCaP cells. These findings suggest that POTEF-AS1 would play a key role in the progression of prostate cancer by repressing Toll-like receptor signaling.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • Research Products

    (7 results)

All 2018 2017 2016 2015

All Journal Article (7 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 7 results,  Open Access: 3 results,  Acknowledgement Compliant: 2 results)

  • [Journal Article] Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer.2018

    • Author(s)
      Takayama KI, Suzuki T, Fujimura T, Takahashi S, Inoue S.
    • Journal Title

      Mol Cancer Res

      Volume: Apr 3 Issue: 5 Pages: 1-11

    • DOI

      10.1158/1541-7786.mcr-17-0471

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine.2018

    • Author(s)
      Fujimura T, Takayama K, Takahashi S, Inoue S.
    • Journal Title

      Cancers (Basel).

      Volume: 10 Issue: 2 Pages: 29-44

    • DOI

      10.3390/cancers10020029

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.2017

    • Author(s)
      Takayama KI, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, Suzuki Y, Inoue S.
    • Journal Title

      Proc Natl Acad Sci U S A.

      Volume: 114 Issue: 39 Pages: 10161-10466

    • DOI

      10.1073/pnas.1706076114

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.2017

    • Author(s)
      Ashikari D, Takayama K, Tanaka T, Suzuki Y, Obinata D, Fujimura T, Urano T, Takahashi S, Inoue S.
    • Journal Title

      Oncogene

      Volume: 36 Issue: 45 Pages: 6272-6281

    • DOI

      10.1038/onc.2017.225

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells.2017

    • Author(s)
      Misawa A, Takayama KI, Fujimura T, Homma Y, Suzuki Y, Inoue S
    • Journal Title

      Cancer Sci

      Volume: 108(3) Issue: 3 Pages: 373-379

    • DOI

      10.1111/cas.13151

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
  • [Journal Article] Increased Expression of Tripartite Motif (TRIM) 47 Is a Negative Prognostic Predictor in Human Prostate Cancer.2016

    • Author(s)
      Fujimura T, Inoue S, Urano T, Takayama K, Yamada Y, Ikeda K, Obinata D, Ashikari D, Takahashi S, Homma Y.
    • Journal Title

      Clin Genitourin Cancer.

      Volume: Jan 28 Issue: 4 Pages: 1558-7673

    • DOI

      10.1016/j.clgc.2016.01.011

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Acknowledgement Compliant
  • [Journal Article] Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase II a trial2015

    • Author(s)
      Fujimura T, Takahashi S, Kume H, Urano T, Takayama K, Yamada Y, Suzuki M, Fukuhara H, Nakagawa T, Inoue S, Homma Y.
    • Journal Title

      BMC Cancer.

      Volume: 15 Issue: 1 Pages: 836-836

    • DOI

      10.1186/s12885-015-1871-z

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi